3D Medicines Inc HKEX:1244:
ENVAFOLIMAB SUPPLEMENTAL APPLICATION FOR CONDITIONAL-TO-REGULAR APPROVAL TRANSITION ACCEPTED BY NMPA
3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Earlier from 3D Medicines
- 3D Medicines Inc Says Zhang Jing Resigns As CFO
- 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
- 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Later from 3D Medicines
- Discloseable transaction
- Interim Report 2026
- Change of principal share registrar and transfer office
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement latest progress in collaboration programs: achievement of pre-specified number of events in the global pivotal phase 3 REGAL trial for 3D189
Follow 3D Medicines into a list and get an email when it puts out news.
Follow 3D Medicines